Objectives. To determine the population structure and antimicrobial sensitivity profile of carbapenem-resistant A. baumannii isolates from different hospitals of Lebanon.
Background
Over the past decade, the incidence of infections due to multidrug-resistant (MDR ) Acinetobacter species has been on the rise worldwide [1] . Nowadays, a clear association had been established between infections caused by carbapenem-resistant Acinetobacter baumannii (A. baumannii) and increased mortality (crude mortality 26%-68%), morbidity, intensive care unit (ICU) , increased stay and cost [2, 3] , thus making this organism a serious threat to our patients. MDR strains of A. baumannii were being recovered in recent years. Also,, Occurrence of MDR Acinetobacter has been recently documented in trauma centers and ICUs in USA and Europe [4, 5, 6] , whereas few studies have reported on emergence of MDR Acinetobacter in Lebanon and other Arab Middle East countries [7] [8] [9] [10] . Our study was conducted to determine the population structure and antimicrobial resistance patterns among imipenem-resistant A. baumannii clinical isolates collected from different hospitals in Lebanon.
Materials and methods

Bacterial isolates
This prospective study was extended over six months period between January 2011 and June 2011. Three hospitals from various geographic areas in Lebanon participated in the study. The study protocol included submission of non-duplicate carbapenem-resistant Acinetobacter isolates obtained from different clinical specimens (Deep tracheal aspirate ,urine ,wound , sputum). Each center tested its own isolates for susceptibility to imipenem by disk diffusion method according to its own practice guidelines. Only imipenem-resistant isolates were submitted to our referral laboratory and included in the study. At the time of analysis, samples were sub-cultured on blood agar base media [BioRad, France] and reidentification was carried out using Remel RapID NF Plus system [Remel, USA] according to the manufacturer's guidelines. Molecular identification at species level was performed by partial sequencing of rpoB (RNA polymerase subunit B) gene (350 pb) [11] .
Antimicrobial susceptibility testing
Confirmatory testing for imipenem resistance was done for all isolates by disc diffusion (10 μg) [13] . Whereas, colistin MIC was determined by Etest [ Biomerieux France]. Only A. baumannii isolates found to be resistant to imipenem were included in the MIC study. The susceptibility to imipenem, meropenem and colistin was determined according to the EUCAST 2014 breakpoints [14] . Susceptibility to tigecycline and sulbactam was determined according to breakpoints recommended by Pachón-Ibáñez et al. [11, 14, 15] and García-Peñuela et al. [15, 16] , respectively ( Table 1 
Molecular analysis
DNA extraction
After overnight growth on nutrient agar [Biolife, Milano, Italy], a loop full of the tested A. baumannii bacteria was suspended in 500 μl of sterile ultrapure water and the QIAamp DNA mini Kit [Qiagen, Hilden, Germany] was used for extraction according to the manufacturer's guidelines.
Multi-Locus Sequence Typing
The internal fragments of seven housekeeping genes including cpn60 (60-kDa chaperonin), fusA (elongation factor EF-G), gltA (citrate synthase), pyrG (CTP synthase), recA (homologous recombination factor), rplB (50S ribosomal protein L2) and rpoB were amplified and sequenced according to the Pasteur scheme available at the following site (http://www. pasteur.fr/mlst). The different sequences were compared to the existing alleles in Pasteur MLST Database. The identification number for sequence types (ST) was given according to their allelic profiles. In order to compare our identified ST(s) to previous identified ST(s) present in MLST Database and to assign them to their corresponding clonal complexes, an eBURST analysis was used (http://eburst.mlst. net/). A clonal complex was defined as a group of similar ST sharing 6 identical loci within 7.
Results
Bacterial isolates. Re-identification of all investigated strains in our laboratory using remel technique showed that all 32 strains were belonged to A. calcoaceticus-A. baumannii complex (99% confidence). Of these, 30 were identified as A. baumannii and 2 as A. pitti strains according to the molecular identification based on partial rpoB sequencing, Only A. baumannii isolates were included for further analysis. The hospital repartition of A. baumannii isolates is shown in Table 2 .
Genetic variability. MLST was performed on all 30
A. baumannii strains to discover the genetic background of A. baumannii strains infected patients in Lebanon. Two sequence types ST2 and ST458 were identified. ST2 was the major sequence type present in 29 strains, whereas ST458 was found sporadically in one strain. By eBURST analysis (Figure 1 ) of MLST database (last updated 07.08.2014), ST2 was the founder of the biggest and principal clonal complex (known as clonal complex 2) formed up to 33 single locus variants [SLV] . ST458 was a singleton and no similar ST has been identified yet. Those STs that can't be linked to any other in the sample are termed singletons and appear as unlinked points Table 2 shows the antibiotic susceptibility profile of all A. baumannii strains to various antibiotic classes. A total of 24 imipenem-resistant strains was detected and the rest 6 strains were imipenem-susceptible. Further susceptibility study of these 24 imipenem-resistant strains was also done by checking MIC of colistin, imipenem, meropenem, sulbactam and tigecycline ( 
TIC (ticarcillin), TCC (ticarcillin/clavulanic acid), TZP (piperacillin/tazobactam), CAZ (ceftazidime),IMP (imipenem), SXT (trimethoprim/ sulfamethoxazole), CS (colistin), GEN (gentamicin), TM (tobramycin), AMK (amikacin), NET (netilmicin), CIP (ciprofloxacin), DOX (doxycycline), MER (meropenem), TIG (Tigecycline) and SAM (sulbactam).
Antimicrobial susceptibility
Discussion
This study demonstrates important results due to the high resistance rates found to common used antimicrobials. All the A. baumannii isolates (except one) belong to international clone 2 (clonal complex 2) , while 82.8 % (24/29) isolates were imipenemresistant. The clone notion in A. baumannii has been appeared for the first time in 1996 when Dijkshoorn et al. found two clones distributed in different hospitals in northwestern Europe and designated them as European clone I and II [17] . After that, these two clones and another clone (designated as European clone III) [18] have been identified throughout the world and then named international clones (I to III) [19] . The dominance of international clone 2 in our collection fits to the global situation where a shift toward this clone has been observed worldwide. It was the largest and the widely distributed clone in 5 continents [20] . The successful emergence of international clone 2 has been attributed to the frequent acquisition of antimicrobial resistance determinants [20] . Further studies using micro-epidemiolgical typing methods like Pulsed Field Gel Electrophoresis are required to evaluate the homogeneity or heterogeneity of the international clone 2 in Lebanon. A. baumannii is an opportunistic pathogen with widespread antimicrobial resistance patterns to commonly used antimicrobials such as; aminoglycosides, extended-spectrum cephalosporins, beta-lactams/sulbactam, antipseudomonal penicillins/betalactamase inhibitors, cotrimoxazole, carbapenems, fluoroquinolones, polymixins, and tetracycline. Magiorakos et al. has categorized MDR Acinetobacter into 3 groups according to the various resistance patterns among [20] . MDR organisms are defined as strains that are resistant to at least 3 antimicrobials representing at least 3 classes. Extensively drug resistant [XDR] organisms are strains susceptible not to more than 2 classes , and Pandrug resistant organisms are strains that are resistant to all classes [21] . In addition to being resistant to carbapenems, beta-lacams/beta-lactamase inhibitor combinations, quinolones, aminoglycosides and cotrimoxazole, only 8.3 % were susceptible to tigecycline and sulbactam. This result is alarming issue since this is an evidence of emergence of XDR A. baumannii in our health care facilities, and colistin become the last resort for treatment of XDR A. baumannii in Lebanon.
It is important to note that resistance to colistin has been reported in some countries [22] . Interestingly, colistin hetero-resistance is much higher than colistin-resistance, and it is also difficult to be detected. First colistin hetero-resistance in A. baumannii had been shown by Li et al. [22] . In this study, colistin-susceptible A. baumannii strains showed early concentration-dependent killing and that suboptimal doses of colistin induce resistance. There is two recent studies from Arab Middle East countries reported A. baumannii colistin resistance isolates, Kuwait (12 %) and Egypt (5 %) (7, 23] . When investigating the dosing regimens in the corresponding Lebanese hospitals during the year preceding the study period, the doses used varied between 1MU every 12 hours and 1MU every 8 hours and rarely reached 2MU every 8 hours, and these doses were lower than that recommended by Michalopoulos and Falagas (3 million IU; 240 mg CMS) every 8 hours as the optimal dose of colistin for critically illpatients with normal renal function [24] . Different dosing, however, was recommended by the manufacturers of European colistin products is 50,000 to 75,000 IU/kg/day of CMS in 2-3 divided doses. This study is recommending to investigate doses higher than the doses mentioned in the leaflet of manufacturers or the regimens used in Lebanon to maintain a full efficacy of colistin.
Tigecycline activity, on the other hand, is compromised by multidrug efflux pump systems such as AdeABC PUMP [ 25] . Peleg et al. showed that the gene coding for the production of this pump can be up regulated under antibiotic pressure causing a rapid rise in MIC to tigecycline upon in vitro passage [26] . Thus, the high rates of tigecycline resistance encountered in our study may be due to the poor understanding of the drug's pharmacokinetics and pharmacodynamics in different infection sites like the bloodstream, and/or in special populations of patients like the critically ill, the obese and many others conditions [27] . 
Conclusion
With the absence of an effective therapy, the wide spread of XDR A. baumannii in our Lebanese health care facilities poses a great danger to patients by increasing mortality, morbidity and hospital stay. Combination therapy of colistin with rifampicin or minocycline might be effective but has yet to be proven against XDR A. baumannii strains. Strict infection control measurements and rational antibiotic use are mandatory to control further aggravation of the antibiotic resistance in Lebanon.
